| Authors: |
Ahn DH; Division of Medical Oncology, Mayo Clinic, Phoenix, AZ., Ridinger M; Cardiff Oncology Inc, San Diego, CA., Cannon TL; Inova Schar Cancer Institute, Fairfax, VA., Mendelsohn L; Carti Cancer Center, Little Rock, AR., Starr JS; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL., Hubbard JM; Division of Oncology, Department of Medicine, Mayo Clinic, Rochester, MN., Kasi A; Division of Medical Oncology, University of Kansas Medical Center, Kansas City, KS., Barzi A; Division of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA., Samuëlsz E; Cardiff Oncology Inc, San Diego, CA., Karki A; Cardiff Oncology Inc, San Diego, CA., Subramanian RA; Cardiff Oncology Inc, San Diego, CA., Yemane D; Cardiff Oncology Inc, San Diego, CA., Kim R; Cardiff Oncology Inc, San Diego, CA., Wu CC; Cardiff Oncology Inc, San Diego, CA., Croucher PJP; Cardiff Oncology Inc, San Diego, CA., Smeal T; Cardiff Oncology Inc, San Diego, CA., Kabbinavar FF; Cardiff Oncology Inc, San Diego, CA., Lenz HJ; Division of Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA. |